ACOTEC
先瑞达

Acotec Scientific Holdings Limited

2024 Business Performance Review

Mar. 2025

TRUSTED INNOVATION
FOR LIFE

ACOTEC
先瑞达

Legal Disclaimer

- This Presentation is strictly confidential and subject to the terms and conditions described below. It is only sent to some people and provided with information about Acotec Scientific Holdings Limited (the "Company") to help you decide whether to conduct in-depth research on the Company. The information contained in this Presentation has not been verified by any regulatory agency in any jurisdiction. The content of this Presentation (regardless of all or part of the content and regardless of the purpose) shall not be copied, distributed or shared directly or indirectly with any person (regardless of whether such person is a member of your company or group). In particular, neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong, Singapore or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. Anyone who obtains this Presentation should understand or be familiar with such restrictions.
- This Presentation and the information contained therein have not been independently verified and are not intended to constitute the basis for making investment decisions. The content of this Presentation does not constitute or form and shall not be construed as a solicitation of an offer for the sale or purchase of securities under any other jurisdiction. Any part of this Presentation does not constitute the basis of any contract or undertaking. Any decision to purchase the Company's securities in a public or private offering shall be based on the prospectus or international offering circular prepared by the Company for the relevant securities offering and any supplementary price information. This Presentation does not include any information or materials that would cause this Presentation to constitute(i) a prospectus under Section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) (Cap.32 of Hong Kong) or the Securities Act of 1933 (as amended) (the "Securities Act"), or an advertisement in relation to a prospectus or proposed prospectus, or an extract from or abridged version of a prospectus under Section 38B of the Companies (Winding-up and Miscellaneous Provisions), or an advertisement, invitation or document which contains any advertisement or invitation under Section 103 of the Securities and Futures Ordinance (Cap. 571 of Hong Kong), or (ii) an invitation to the public made in Hong Kong without abiding by Hong Kong law or introducing exemptions under Hong Kong law. This Presentation is subject to change without notice.
- The Company's securities have not been and will not be registered under the Securities Act or the securities law of any state in the United States, and may not be offered or sold in the United States without registration or obtaining relevant applicable exemptions. Neither this Presentation nor its content constitutes or forms, and shall not be construed as part of an offer or solicitation of an offer to subscribe for securities in the United States. The Presentation shall not be carried or transmitted to the United States (including its territories and commonwealths, any state or the District of Columbia), or distributed directly or indirectly in the United States (including its territories and commonwealths, any state or District of Columbia). The Company's securities will not be offered or sold in the United States except for transactions that are not subject to exemptions under the provisions of the Securities Act or not subject to the Securities Act.
- By participating in or by reading this Presentation, you are recognized to have made representations and warranties to the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you and any you represent (if any) are either (i) a "qualified institutional buyer" (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States.. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.
- The information in this Presentation is provided by the Company. This Presentation is not intended to be comprehensive or to contain all the information you may need to evaluate the Company. Regarding the accuracy, reliability, correctness, reasonableness, fairness or completeness of this Presentation or any information therein, or any oral or written communication regarding the evaluation of the Company, none of the parties (to avoid ambiguity, including but not limited to the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors) has or will make any express or implied statement or guarantee, and shall not, within the scope permitted by law, assume any liability arising therefrom. In particular, regarding the realization or reasonableness of any assumptions, speculations, goals, estimates or prospects contained in this Presentation, no express or implied statements or guarantees are made, nor should you rely thereon. Some of the information contained herein comes from different sources, including some third parties, and has not been independently verified by the Company. For the losses caused to you or any person using or relying on the information contained or disclosed in this Presentation, the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents or representatives shall take no responsibility (whether in negligence or otherwise). The use of registered trademarks, commercial trademarks and logos or photographic materials within this Presentation are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.
- This Presentation is subject to the disclaimer and restrictive language contained therein. Any person shall make their independent evaluation and analysis, and shall not use any information mentioned, discussed or quoted in therein as the basis for their actions. You understand and assure the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you are a professional investor and have the knowledge, experience and ability required to evaluate the Company, you will make independent evaluation of the Company, its securities and all the information provided, and you have or will obtain independent advice for the evaluation of the Company's securities.
- This Presentation may contain the Company's current beliefs and expectations regarding the indicated future dates. Such forward-looking statements are based on some assumptions about the Company's operations or factors outside the Company's control, and may be affected by a number of known and unknown factors. Therefore, the Company's actual performance may be materially different from these forward-looking statements. You shall not rely on such forward-looking statements. The Company, the parties involved in the issuance of the Company's securities, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors shall not be obliged to update or revise such forward-looking statements in response to new information, events or circumstances that occur after these dates.
- This Presentation and the information contained therein are strictly confidential. This Presentation and the information contained therein shall not be copied, reproduced, or transmitted to others in any form, or disclosed for any purpose (whether in whole or in part). Failure to comply with these restrictions may constitute a violation of the law and may result in legal or regulatory action. By receiving this Presentation or the information therein, you agree (1) that you have read and agree to abide by the requirements in this disclaimer; and (2) that you will keep the information contained in this Presentation strictly confidential.
- By participating in and accepting this Presentation, you agree to maintain the absolute confidentiality of the information contained in this Presentation and accept the restrictions and other conditions stated therein. Failure to comply with these restrictions and conditions may violate relevant laws and regulations and result in legal or regulatory measures.

AGOTEC
先瑞达

01 2024 Financial Performance Review

02 The Progress of CCT Implementation

03 Product Commercialization

04 R&D, Product Approvals, and Manufacturing Status

05 Q&A

TRUSTED INNOVATION
FOR LIFE

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

01

2024 Financial Performance Review

2024 Financial Performance Review (1/3)

The business sustained rapid growth while achieving a more diversified income

(In millions RMB)



(In millions RMB)

Overseas Revenue



SFA DCB | BTK DCB | Venous intervention, vascular access and other products

- Total revenue reached **RMB 534mn** in 2024, representing a **12.7% increase** compared to 2023.
- Revenue generated from DCBs in 2024 was RMB 320mn, with SFA DCB contributing RMB 267mn and BTK DCB accounting for RMB 53mn.
- Revenue of **Venous Intervention, vascular access, and other products** was **RMB 214mn**, **achieving 42.2% YoY growth and contributing 40% of the total revenue**, becoming a significant driver for the overall business growth.
- **Overseas product sales** contributed **approximately 25mn revenue,** with **61% YoY increase.**

Gross Profit & Gross Profit Margin

(In millions RMB)



Gross Profit Margin | Gross Profit

- Full year **gross profit of RMB 403mn in 2024**, with **a gross profit margin** of approximately **75.4%**. The slight decrease in gross profit margin were mainly due to: 1) revenue from venous products is growing rapidly and its contribution to the total revenue is increasing, while the margin is lower than that of DCBs; 2) The overseas sales of DCB products are growing rapidly, but the gross margin from oversea sales is lower than that from the domestic market.

2024 Financial Performance Review (2/3)

TRUSTED INNOVATION
FOR LIFE

R&D expenses



- In 2024, the R&D expenses were about **217mn**, up 14% YoY. This increase is due to both the addition of **new projects and the expansion of the R&D team, as well as higher costs as key projects progress.**
- The R&D expense ratio was around 40%, reflecting the company's effective cost control and the realization of economies of scale.

Selling and distribution expenses



- In 2024**, sales expenses** were approximately **93mn**, a **4.9% decrease YoY**. The selling expense ratio declined by 4ppt to 17%, primarily attributable to the company's improved operational efficiency and the cost control capabilities.

Administrative expenses



- In 2024, the operational efficiency improvement also resulted in a **22.5% decrease in administrative expenses to 65mn, with expense ratio falling to 12%.** Mainly because: 1) Consulting fees related to partial offer and CCT were no longer incurred in 2024 and 2) The new facility has been put into operation, therefore the related depreciation and amortization expenses have been reallocated from administrative expenses to respective department budgets.

2024 Financial Performance Review (3/3)

TRUSTED INNOVATION
FOR LIFE

Profit from operations & Net Profit

(In millions RMB)



- In 2024, the **profit from operation was 64 mn**, marking a 155.9% increase from 2023. The operating profit directly reflects our enhanced profitability and effective cost management.
- The company reported a net profit of **52.3mn, up 260.9% YoY increase**. With a robust and sustainable self-funding ability, the ongoing inflow of operating cash has optimized our asset structure, enabling further investment in R&D and commercial activities.

Liquidity and Financial Resources



- At the end of 2024, the Company had a total of **RMB 864mn** in financial resources available.
- The ample financial reserves on hand ensure the company's continued stable operation and support ongoing exploration of business development opportunities.

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

02

The Progress of CCT Implementation

Key Updates on Collaboration with BSC: Product Commericalization

TRUSTED INNOVATION
FOR LIFE

Global Expansion landscape of Collaborative Products

With the launch of products in China and globally, the scope and geographical coverage of collaboration are continuing to expand.

Overseas Countries

SFA DCB
AcoArt Orchid®

BTK DCB
AcoArt Tulip® & Litos®

- **Distribution Agreement signed** for **SFA & BTK DCB sales in overseas market in 2023.**
- Acotec has been actively progressing through the regulatory registration and market access processes in various overseas countries.

SFA DCB and BTK DCB have expanded their coverage in the fellowing countries in 2024 and will reach more in the future.

England Sweden Finland Netherlands Austria Poland Chile ...

The Mainland China

- Distribution Agreement signed for Selected Approved Coronary Products, BSC has commenced selling Acotec products in mainland China market.
- The collaboration scope will continue to broaden with the approval of more products in the future.

PTCA Balloon YAN

Micro-catheter Vericor-14®

CTO small Balloon RT-Zero®

Coronary DCB AcoArt Camellia®

Cardiac Valve Balloon RunFlow®

...

Hong Kong and Taiwan

PI+Coronary Products

- In 2024, Acotec and BSC have begun to establish cooperation on the commercialization of multiple **peripheral and coronary products** in Hong Kong and Taiwan.

Key Updates on Collaboration with BSC: R&D

In 2024, Acotec and BSC initiated a collaborative partnership in R&D, focusing on the co-development of products.

ACOTEC 先瑞达

Boston Scientific

Collaborative Design Input	Collaborative Design Input
	Confirming Product Design
Product Development	
	Confirming Finalized Product
Product Registration	

Product Commercialization

Upon market launch of co-development products, BSC hold the galobal commercialization rights for these products.

03

Product Commercialization

We maintained market competitiveness through our reliable products and first-mover advantages

TRUSTED INNOVATION
FOR LIFE



1800

Hospital Admitted

SFA DCB
AcoArt Orchid® & Dhalia®

- Acotec's SFA DCB is the first approved product in China. Leveraging its early-mover advantage and outstanding clinical performance, we have established a strong competitive edge and remain the leading brand in market share.
- **Winning in Hebei+ Sanming VBP** accelerates the hospital listing and coverage, driving fast-growing clinical implantation
- **We won bids in the Henan provincial VBP in 2025.**

820

Hospital Admitted

BTK DCB
AcoArt Tulip® & Litos®

- As the exclusive product provider, we are advancing domestic BTK treatment standards through our comprehensive one-stop therapeutic device portfolio.

Acotec@CEC2024



Acotec@SJVF2024

BTK Surgery Proctorship

BTK DCB-China Real World Data Release @LINC



We secured rapid market expansion through targeted penetration and clinical adoption support

TRUSTED INNOVATION
FOR LIFE

1760

Hospital Admitted

Peripheral Aspiration System
AcoStream®

- With urgent demand in lower-tier markets, our two-generation product portfolio has not only strengthened our competitive advantage but also emerged as a key growth engine for our business.
- **Winning the bid in Henan's VBP in 2023** has accelerated product admissions in hospitals and increased implanting volumes.
- **We won bids in the Henan provincial VBP again in 2025.**

680

Hospital Admitted

RFA System
AcoArt Cedar®

- We are systematically expanding hospital coverage while advancing physician capability-building programs to accelerate therapy adoption.
- **Winning the bid in Henan's VBP in 2023** has accelerated product admissions in hospitals and increased implanting volumes.
- **We won bids in the Henan provincial VBP again in 2025.**

AcoStream Thrombectomy Case Competition

AcoStream Clinical Case Sharing


横扫血栓 | AcoStream在急性肠系膜上动脉栓塞及下肢动脉血栓清除应用一例

北京先瑞达 北京先瑞达 2024年08月05日 17:00 上海

内容总览

血栓脱落到达肠系膜动脉后发生栓塞会引起梗阻，进一步导致供血肠管发生急性缺血甚至坏死，并且肠系膜动脉栓塞发病急、进展快，所以早期诊断及时治疗十分关键，一经确诊后需尽早进行介入手术治疗。目前常用方法包括：导管吸栓、取栓，溶栓导管溶栓，球囊扩张，支架植入等。

急性下肢动脉栓塞也是外周血栓常见疾病之一。血栓掉落至下肢动脉会造成急性下肢动脉缺血，需要及时处理复通血流。近日，来自北京平谷区医院的狄长安教授使用一根AcoStream血栓抽吸导管成功处理了一例肠系膜上动脉血栓合并下肢动脉血栓的患者，先后恢复肠系膜动脉和下肢血供，快速解除急症，挽救了患者生命，并在患者费用受限的情况下实现了经济效用和临床获益最大化。

RFA System Experience Sharing Seminar

Varicose Vein- Free Medical Consultation

04

R&D, Product Approvals, and Manufacturing Status

In 2024, we successfully launched 7 innovative products to the market, achieving a record high in product approvals

TRUSTED INNOVATION
FOR LIFE

7 New Approvals *(2024/12/31)*

Vascular Surgery

Delivery Catheter for Aspiration Catheter

Introducer Sheath Set Acotrace

Nephrology

AV Scoring Balloon Peridge®

Cardiology

Coronary CTO Retrograde Micro-Catheter Vericor-RS®

Coronary High-Pressure PTCA Balloon YIYAN



TAVR Balloon RunFlow®

Coronary Paclitaxel-coated Balloon AcoArt Camellia®

7 Products have been applied for registration with the NMPA

- Coronary Sirolimus DCB
- Intracranial DCB
- Vertebral DCB
- Peripheral Scoring Balloon
- Peripheral Coil
- Peripheral Thrombectomy Device
- High-pressure Balloon

Products undergoing clinical trials

BTK DCB (U.S.)

Peripheral Sirolimus DCB

.....

We have built a comprehensive product portfolio, leveraging our 4 platform technologies to drive efficient R&D and achieve scale effects

TRUSTED INNOVATION
FOR LIFE

4 Platform Technologies

- Drug-coating Technology
- Aspiration Platform Technology
- Polymer Material Technology
- RFA Technology

4
Department Coverage

22
Approved Products

10
Products under development/ registration/ clinical trials

24
Overseas countries converge



Comprehensive Solution for Vascular Diseases

Acotec's intracranial DCB has demonstrated superior clinical results, with the study published in JNIS, a leading neurointerventional journal

TRUSTED INNOVATION
FOR LIFE

Clinical Trial



The restenosis rate at 6-month follow-up



Superior efficacy clinical trial results

The target lesion restenosis rate at 6-month

	DCB Group	Stent Group	Rate difference and 95% CI
Number of Follow-up Cases	73	76	NA
Number of Cases with Lesion Restenosis	5	25	NA
Restenosis Rate	6.85% (5/73)	32.89% (25/76)	-19.02% (-27.42, -6.18%)

The research findings were published in JNIS

- ✓ **The AcoArt sICAS, led by Professor Miao Zhongrong's team from Beijing Tiantan Hospital**, aimed to investigate the **efficacy and safety** of the AcoArt Daisy **intracranial DCB** and the intracranial bare metal stent (**BMS**) in the application of sICAS.
- ✓ The 6-month follow-up results of this clinical trial were published on January 13, 2025, in JNIS, which is a **leading authoritative journal in the field of neurointerventional, focusing on the latest technological advances, clinical practices, and fundamental scientific research in the realm of neurointerventional surgery.**
- ✓ The trial results indicate that during the 6-month follow-up period, **DCB significantly reduced the rate of restenosis compared to BMS, without increasing the incidence of target vessel-related stroke or death, suggesting its potential as an effective future treatment for sICAS.**


Vascular neurology

Original research

Comparison of drug-coated balloon with bare-metal stent in patients with symptomatic intracranial atherosclerotic stenosis: the AcoArt sICAS randomized clinical trial

The vertebral artery DCB has shown excellent clinical trial results, and its launch will further strengthen the company's position in the neurointerventional field.

TRUSTED INNOVATION FOR LIFE

Clinical Trial

Treatment Group
AcoArt Verbena®
& Vinca® DCB



Control Group
Apollo® Stent



Study Objective
To verify the efficacy and safety of Vertebral DCB in the endovascular treatment of vertebral artery origin (VAO) stenosis

Study Design
Prospective, multicenter, randomized controlled non-inferiority trial

Patients Enrollment
180 patients
1:1 allocate to the DCB group and the Stent group.

Primary Study Endpoints
12-month follow-up:
Restenosis rate of the target lesion

The restenosis rate at 12-month follow-up



Superior efficacy clinical trial results

	DCB Group	Stent Group	Rate difference and 95% CI
Number of Follow-up Cases	69	67	NA
Number of Cases with Lesion Restenosis	9	25	NA
Restenosis Rate	13.04%	37.31%	-24.27% (-38.31%, -10.23%)

VAO stenosis is a significant factor in ischemic stroke occurrence

Ischemic strokes account for **70.2%** of all strokes



25%~40% of ischemic strokes occur in the posterior circulation

- Stroke is the second leading cause of death and the third leading cause of disability globally.
- 25-40% of ischemic strokes occur in the posterior circulation, with 9-33% having VAO stenosis or occlusion.
- **Treating VAO stenosis is significant for stroke prevention.**

Source: Frost & Sullivan research report; CIC research report.

The market for DCB treatment of vertebral artery stenosis holds promising prospects

2030E

216.2 thousand

- Traditional stent/balloon angioplasty may lead to neointimal hyperplasia and relatively high rates of restenosis. DCB treatment has the advantages of no implants left in the blood vessels, offers promising prospects for future treatments.
- According to CIC Consulting research, it is projected that by 2030, the number of surgeries for ischemic stroke treated with DCB will be approximately 216,000.

Acotec has established a comprehensive coronary product portfolio, with another blockbuster product nearing approval - the Coronary Sirolimus DCB

TRUSTED INNOVATION
FOR LIFE

Clinical Trial- Coronary Sirolimus DCB

Treatment Group Acotec-Coronary Sirolimus DCB	Control Group Yinyi-Bingo Paclitaxel DCB

Study Objective	To verify the efficacy and safety of Coronary Sirolimus DCB in the treatment **of bifurcation lesions** in coronary arteries
Study Design	Prospective, multicenter, randomized controlled non-inferiority trial
Patients Enrollment	230 patients 1:1 allocate to the Treatment group and the Control group
Primary Study Endpoints	At 9 months post-surgery, the diameter stenosis rate (DS.%) of the target lesion branch vessel as shown by angiography.

	Treatment Group	Control Group	Rate difference and 95% CI
Number of cases included in the PPS	91	94	-
The diameter stenosis rate of the target lesion	30.52%	33.46%	-1.93% (-5.79%, 1.92%)

✓ **The non-inferiority hypothesis is established**



15%-20%

Bifurcation lesions are present in patients treated with PCI

- ✓ Upon approval, it will become China's first coronary sirolimus DCB indicated for bifurcation lesions, providing a safe and effective treatment option.
- ✓ Multiple clinical studies have demonstrated that bifurcation lesion management should be kept as simple as possible. The "leave-nothing-behind" approach with DCB preserves future treatment options for patients.



"In bifurcation lesions, after predilatation with conventional balloons, DEB treatment of both the main branch and the side branch is a safe and feasible approach. Stent implantation remains necessary as a bailout strategy in case of relevant dissections (Type C-F or flow-limiting) after DEB treatment."

— 2013 Update of the German Consensus Group on Drug-Eluting Balloons

"Bifurcation lesions are recommended for drug-eluting balloons alone or as an alternative therapy to drug stents."

— "Chinese Consensus on Clinical Application of Drug-Coated Balloons (2016) "



The BTK DCB AcoArt Litos® : Multiple clinical trial sites activated in U.S./Europe, patient enrollment ongoing

TRUSTED INNOVATION
FOR LIFE

AcoArt Litos®

ACOTEC
先瑞达
Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司

自願性公告
ACOART LITOS® 的IDE申請獲美國FDA批准

The IDE application received FDA approval on Nov 29, 2023



U.S. FOOD & DRUG

June 5, 2019

Acotec Scientific Co., Ltd.
Yi H. Sarah Ohlay
President
CardioMed Device Consultants
1783 Forest Drive, Suite 254
Annapolis, MD 21401

Re: Q180933
Trade/Device Name: Acotec Litos Paclitaxel Releasing Peripheral Balloon Dilation Catheter
Received: May 13, 2019

Dear Mr. Ohlay:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has received the above submission requesting designation as a Breakthrough Device. The proposed indications for use includes, "The Acotec Paclitaxel Releasing Peripheral Balloon Dilatation Catheter is indicated for percutaneous transluminal angioplasty, after pre-dilatation, of de novo or restenotic lesions up to 300 mm in length in native infrapopliteal arteries with reference vessel diameters ranging between 2.0 mm and 4.0mm, including anterior tibial artery, tibioperoneal trunk, peroneal artery and posterior tibial artery." We are pleased to inform you that your combination product and proposed indication for use meet the criteria and have been granted designation as a Breakthrough Device. Please refer to the FDA guidance document entitled "Breakthrough Devices Program", for more information regarding the program, available at https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM583664.pdf.

We recommend you review the FDA guidance document for the Breakthrough Devices Program referenced above for the available mechanisms for obtaining feedback from the Agency on device development for designated breakthrough devices. When submitting any new requests, please reference Q180933. Any new

Litos was granted designation as Breakthrough Device from FDA in 2019

- ✓ US and European sites simultaneously activated
- ✓ Patient enrollment progressing systematically
- ✓ US BTK surgery volume is 150,000/year, indicating broad application prospects for DCB

FIRST COAST CARDIOVASCULAR INSTITUTE

COLUMBIA UNIVERSITY

SOUTH CHARLOTTE GENERAL & VASCULAR SURGERY

UT Southwestern Medical Center

- We have partnered with several renowned sites and PIs in the peripheral vascular disease field in the U.S.

- Acotec BTK DCB obtained CE Mark in 2014 and has been clinically applied in Europe for nearly 10 years. European PIs are familiar with the product and have extensive clinical experience.
- Two sites have activated in Europe.

We have expanded our manufacturing capabilities in the upstream of the industry chain and create a competitive edge in R&D and production

TRUSTED INNOVATION
FOR LIFE



Hydrophilic Lubricious Coatings

- We have gradually mastered advanced hydrophilic lubricating coating technology, which has superior performance to international products. This will enhance our product performance, significantly reduce raw material costs, and shorten the overseas procurement cycle.

Enhancing R&D Efficiency
We utilize our in-house technology to expedite prototyping. This allows for more trial-and-error opportunities, enhancing R&D efficiency while maintaining quality.

Self-sufficiency in producing raw materials
Our self-produced raw materials have achieved the desired quality level, and we are gradually replacing some of the originally imported materials with our own.

Reduce R&D and production costs
The efficient R&D, as well as a high proportion of self-produced raw materials, have helped us achieve cost reduction and efficiency improvement.



Laser Cutting



Laser Welding

Extrusion & Balloon Forming

Coiling



Catheter Assembly



Braiding

We are enhancing manufacturing capacity in Beijing & Shenzhen to meet increasing market demand

TRUSTED INNOVATION
FOR LIFE

2+M Units/Year

One-shift Production Capacity, can double by working in two shifts
(After Beijing & Shenzhen New Facility fully put in use)

1+M Units/Year

Production Capacity
can double by working in two shifts

The gross floor area of production facilities	
30,800m²	6,220m²
Beijing	Shenzhen

Production Capacity		
997,130	465,792	46.7%
Production Capacity	Actual Production Volume	Utilization Rate

Beijing Manufacturing Facility

Shenzhen Manufacturing Facility


New Beijing Facility

ACOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

05

Q&A

AGOTEC
先瑞达

THANKS!

谢谢！

TRUSTED INNOVATION
FOR LIFE

Products and Pipeline-Full Product Portfolio (1/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Vascular Surgery	AcoArt Orchid® & Dhalia®/Orchid Plus★ Note 1	Superficial femoral artery (SFA) and popliteal artery (PPA) disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
	AcoArt Tulip®& Litos®★	Below-the-knee (BTK) artery disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
				U.S.	✓	FDA IDE Approval		
	AcoArt Iris® & Jasmin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	AcoArt Lily® & Rosmarin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	Peripheral Aspiration System (AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	NMPA Approval★	/
				Brazil	✓		ANVISA Approval★	/
	Radiofrequency Ablation System (AcoArt Cedar®)	Saphenous varicose veins	RF platform	China	✓	✓	NMPA Approval★	/
	Peripheral Support Catheter (Vericor®)▲	Peripheral CTO lesion	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
				U.S.	✓		FDA Approval★	/
				Brazil	✓		ANVISA Approval★	/
				Thailand	✓		TFDA Approval★	/
				Japan	✓		MHLW Approval★	/
	PTA Balloon (P-Conic®)	PTA	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	2nd Gen Peripheral Aspiration System (2nd Generation AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Introducer Sheath Set Acotrace	PTA	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Delivery Catheter for Aspiration Catheter	DVT	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Lower Limb Sirolimus DCB	SFA and PPA disease	Drug coating technology	China	✓	✓		2026
	Peripheral Scoring Balloon	SFA and PPA disease	Polymer materials	China	✓	✓		2025
	Peripheral Coil	Embolization	Polymer materials	China	✓	✓		2025
	Peripheral Thrombectomy Device	DVT, ALI and PE	Polymer materials	China	✓	✓		2025
	Microguidewire▲	PTA	Polymer materials	China	✓	Exempted from clinical trial		2025

★Core product ☆ Indication expansion of core product ★Commercialization

▲Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (免於進行臨床試驗醫療器械目錄) promulgated by the NMPA, as amended.

Note 1: We have been continuously improving the performance of AcoArt Orchid® & Dhalia™. As advised by NMPA and as part of our business strategy, we decided not to register Orchid Plus as a separate product. Alternatively, we applied to register Orchid Plus as an upgrade version of AcoArt Orchid® & Dhalia® with improved delivery balloon catheter system, and received the revised NMPA approval for AcoArt Orchid®& Dhalia® in November 2021.

Products and Pipeline-Full Product Portfolio (2/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Cardiology	Semi-compliant PTCA Balloon (YAN)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Recanalization Balloon (RT-Zero®)▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Antegrade Micro-Catheter (Vericor-14®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
				Japan			MHLW Approval★	/
				Thailand			TFDA Approval★	/
	Coronary Retrograde Micro-Catheter (Vericor-RS®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary High-Pressure Balloon (YIYAN)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	AcoArt Camellia® (DCB)	Coronary small vessel diseases	Drug coating technology	China			NMPA Approval★	
	Cardiac Valve Balloon RunFlow®	TAVR	Polymer materials	China			NMPA Approval★	
	Coronary Micro-Catheter (Vericor-S2®) ▲Note 2	PCI	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary Sirolimus DCB	Bifurcation lesions	Drug coating technology	China				2025
	Coronary IVL System	Coronary lesion calcium	Polymer materials	China				2027
Nephrology	AcoArt Orchid®& Dhalia®/Orchid Plus☆(DCB)	Arteriovenous fistula stenosis	Drug coating technology	China			NMPA Approval★	/
	Paclitaxel Coated High-pressure Balloon (ACOART AVENS®) ▲	AVF PTA procedure	Drug coating technology	China			NMPA Approval★	/
	AV Scoring Balloon (Peridge®)	AVF PTA procedure	Polymer materials	China			NMPA Approval★	/
	High-Pressure Balloon	AVF PTA procedure	Polymer materials	China				2025
Neurology	Intracranial PTA Balloon (NEO-Skater®)▲	Intracranial PTA procedure	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	AcoArt Verbena®& Vinca® (DCB)	Vertebral atherosclerotic stenosis	Drug coating technology	China				2025
	AcoArt Daisy® (DCB)	Intracranial atherosclerotic stenosis	Drug coating technology	China				2025

★Core product ☆ Indication expansion of core product ★Commercialization

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.

Note 2. Coronary Micro-Catheter (Vericor-S2®) obtained the registration approval from the NMPA on January 20, 2025.